SecBot SecBot

GANX

Gain Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001819411 Biotech & Drug Discovery
$1.15 −0.11 (−8.73%)
Oct 26 4:00 PM ET · prev $1.26
Market cap
$56.3M
Micro cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$8.00
+596% · range $5.00–8.00
Next earnings
Nov 18
in 22 days · EPS est. −$0.13
1 year
−41.0%
from $1.95 · Oct 27
30 days
−35.0%
from $1.77
52-week range
$1.15–4.18
at the low
Avg volume 20D
689.1K
Oct 22 spike 2.75M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 2 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Gain Therapeutics announced long-term open-label extension data from its Phase 1b study of rexaceract in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.158 → −$0.128 over 90 days.

  • TrendDOWNTREND

    32% below its 50-day average. New closing low $1.15 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED154,524$313.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLPNEAR_EXIT78,206$158.8K
COMMONWEALTH EQUITY SERVICES, LLCADD58,456$118.7K
JANE STREET GROUP, LLCTRIM55,628$112.9K
GROUP ONE TRADING LLCTRIM3,808$7.7K
UBS Group AGDOUBLED220,489$427.7K
COMMONWEALTH EQUITY SERVICES, LLCDOUBLED29,703$57.6K
SIMPLEX TRADING, LLCTRIM13,439$26.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +596%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 31, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 11, 2026BTIG
REITERATE
REITERATEBuy
Jul 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 30, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 15, 2026
HASLER HANS PETER
Director
AWARD25,000 sh
Jul 15, 2026
Riley Jeffrey Scott
Director
AWARD25,000 sh
Jul 15, 2026
Melincoff Gwen A
Director
AWARD25,000 sh
Jul 15, 2026
Islam Khalid
Director
AWARD25,000 sh
Jul 15, 2026
Nicaise Claude
Director
AWARD25,000 sh
Jul 15, 2026
GOLDSTEIN DOV A MD
Director
AWARD25,000 sh
Mar 24, 2026
Mack Gene
CEO, President
AWARD200,000 sh
Mar 24, 2026
Fuggetta Gianluca
See Remark
AWARD50,000 sh

Earnings setup

Estimates
Nov 18
reports in 22 days
−$0.13
EPS estimate, this quarter
+19%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.13-$0.13–-$0.12-0.7%$0.00
Next Q-$0.14-$0.16–-$0.11-6.6%$0.00
Current FY-$0.51-$0.53–-$0.48-1.7%$0.00
Next FY-$0.69-$1.11–-$0.49-25.8%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 1, 2026 Press
Gain Therapeutics presented Phase 1b open-label extension data for rexaceract (GT-02287) at the MDS Congress, showing…
Impact 4/10
Oct 1, 2026 FDA
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease pr
Oct 1, 2026 SEC
Gain Therapeutics announced long-term open-label extension data from its Phase 1b study of rexaceract in Parkinson's…
8-K — Impact 6/10
Aug 11, 2026 SEC
Gain Therapeutics reported Q2 2026 EPS of -$0.11, beating consensus of -$0.15 by 26.7%, with net loss narrowing to…
PRESS-RELEASE — Impact 6/10
Jul 16, 2026 SEC
Gain Therapeutics filed an 8-K announcing that its cash and cash equivalents are expected to fund operations into Q2…
8-K — Impact 4/10
Jul 15, 2026 Insider
HASLER HANS PETER was granted 25,000 shares
Director
Jul 15, 2026 Insider
Riley Jeffrey Scott was granted 25,000 shares
Director
Jul 15, 2026 Insider
Melincoff Gwen A was granted 25,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
GANX Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Oct 1, 2026
FDA
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants…
Sep 29, 2026
Press release
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
Sep 17, 2026
Press release
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology…
Aug 11, 2026
Earnings
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
Aug 10, 2026
Earnings date
GANX Q2 2026 Earnings Scheduled — 2026-08-10

SecBot reports

7 filings · 4 press releases · 4 bullish · 0 bearish · 3 neutral
All GANX filing & press-release reports (11)